ClinicalTrials.gg
RecruitingNCT06089616FOPalUpdated Oct 23, 2026

A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

An observational study in Fibrodysplasia Ossificans Progressiva, sponsored by Ipsen. Recruiting at 5 sites in 2 countries. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ipsen · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Myositis Ossificans by Ipsen — 1 open to participants now, 1 under way, none of them phase 3. Myositis Ossificans · Ipsen.

Started
2024
the only one that year
Observational
3 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Myositis Ossificans by Ipsen, this one is the only one that started in 2024, is one of 3 observational ones, and was the 10th registered.

Myositis Ossificans

24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.

Browse Myositis Ossificans studies →

Open to participants now

1 of the 10 studies in Myositis Ossificans by Ipsen is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 4 Myositis Ossificans studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 8 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myositis Ossificans by Ipsen, or all of them as a file.
02

Study summary

The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).

FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).

HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).

This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.

The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.

This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.

In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.

03

Conditions studied

  • Fibrodysplasia Ossificans Progressiva

Browse trials for

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults and children with FOP who have been prescribed palovarotene, as per local label, by their treating physician for which informed consent has been obtained and maintained. Participants cannot be included if they are currently participating in a palovarotene clinical trial or an interventional clinical trial for FOP or if they have any contraindication for palovarotene (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
  • Signed as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.

Exclusion criteria

Exclusion Criteria :

  • Currently participating in a palovarotene clinical trial;
  • Currently participating in any interventional clinical trial for FOP;
  • Have any to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Exposed Cohort

    Participants treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information)

  • Unexposed Cohort

    Participants untreated with palovarotene

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene

    Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC).

    Time frame: From Baseline up to 30 days after the last palovarotene dose.

  2. Percentage of Participants With Serious and Non-serious treatment-related TEAEs

    Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

    Time frame: From Baseline up to 30 days after the last palovarotene dose.

  3. Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene

    Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

    Time frame: From Baseline up to 30 days after the last palovarotene dose.

  4. Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene.

    Adverse events will be coded according to MedDRA and will be classified by PT and SOC.

    Time frame: From Baseline up to 30 days after the last palovarotene dose.

Secondary outcomes

  1. Change from Baseline in Cumulative Analogue Joint Involvement Scale (CAJIS) total score

    The CAJIS is an objective measure of joint movement completed by the Investigator to document total joint involvement. The CAJIS total score is calculated as the sum of the scores of all joints/regions and ranges from 0 (no involvement) to 30 (maximally involved).

    Time frame: From Baseline and every six months up to eleven years.

  2. Change from Baseline in use of assistive devices

    Assistive devices is a questionnaire to assess the assistive devices used by particpants and adaptations for their daily living.

    Time frame: From Baseline and every six months up to eleven years.

  3. Change from Baseline in percent of worst score for Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) total score

    Fibrodysplasia Ossificans Progressiva-Physical Function Questionnaire (FOP-PFQ) consists of questions which are scored on a scale of 1 to 5, lower scores indicating that the participant has more difficulties.

    Time frame: From Baseline and every six months up to eleven years.

  4. Change from Baseline in observed and percent predicted Forced Vital Capacity (FVC)

    The lung function parameters of observed FVC (liters) and percent predicted FVC are obtained by spirometry.

    Time frame: From Baseline and every six months up to eleven years.

  5. Change from Baseline in observed and percent predicted Forced Expiratory Volume in one second (FEV1)

    The lung function parameters of observed FEV1 (liters) and percent predicted FEV1 are obtained by spirometry.

    Time frame: From Baseline and every six months up to eleven years.

  6. Change from Baseline in absolute and percent predicted FEV1/FVC ratio

    The lung function parameters of the absolute and percent predicted FEV1/FVC ratio are obtained by spirometry.

    Time frame: From Baseline and every six months up to eleven years.

  7. Change from Baseline in observed and percent predicted Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)

    The lung function parameters of observed (traditional unit of mL/min/mmHg or SI unit of mmol/min/kPa) and percent predicted DLCO is obtained by the DLCO test.

    Time frame: From Baseline and every six months up to eleven years.

  8. Change from Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) physical and mental function (mean global physical and mental health score converted into T-scores) for participants ≥15 years old

    PROMIS Global Health Scale for the adult version, the global physical health and global mental health scores will be calculated as follows: * Global physical health scores will be calculated as the sum of scores from Questions 3, 6, 7 and 8 and will range from 4 (worse health) to 20 (better health); * Global mental health scores will be calculated as the sum of scores from Questions 2, 4, 5 and 10 and will range from 4 (worse health) to 20 (better health).

    Time frame: From Baseline and every six months up to eleven years.

  9. Change from Baseline in PROMIS overall quality of life (QoL) (mean total score converted into T-scores) for participants <15 years old

    PROMIS Global Health Scale for the paediatric version, the total score will be calculated as the sum of scores from the first 7 questions and will range from 7 (worse health) to 35 (better health). If more than 3 questions contributing to the total score are missing, the total score will not be calculated. It will be considered as missing.

    Time frame: From Baseline and every six months up to eleven years.

  10. Change from Baseline in annualized number of Investigator-reported flare-ups by body location and overall

    The annualized number of flare-ups will be derived from the number of flare-ups the participant experienced since last visit.

    Time frame: From Baseline and every six months up to eleven years.

  11. Number of flare-up outcomes

    Number of flare-up outcomes as measured by new bone growth, restricted movement at each visit will be reported.

    Time frame: From Baseline and every six months up to eleven years.

  12. Flare-up Duration

    Flare-up duration will be assessed by body location and overall, at each visit.

    Time frame: From Baseline and every six months up to eleven years.

  13. Number of flare-ups

    Time frame: From 12 months before inclusion Baseline up to eleven years.

  14. Movement mobility change

    Assessed by key body location: better movement/the same movement/slightly worse movement/moderately worse movement/severely worse movement)

    Time frame: From Baseline and annually up to eleven years.

  15. Number of locations impacted per participant

    Time frame: From Baseline and annually up to eleven years.

  16. Evolution of impacted location (how many times a location is impacted) per location

    Time frame: From Baseline and annually up to eleven years.

  17. Movement mobility outcomes: Percentage of participants with new bone growth overall and by flare-up status

    The number of extra bone growths, location of the extra bone growth, whether it was preceded by injury, illness, vaccination and/or other events, whether it was preceded by pain, soft tissue swelling, decreased range of motion, stiffness, redness, or warmth, extra bone growth start and stop date and whether it is ongoing, will be collected.

    Time frame: From Baseline and every six months up to eleven years.

  18. Percentage of participants with any fractures overall

    Assessed by radiological imaging and clinical examination.

    Time frame: From baseline up to 30 days after the last palovarotene dose.

  19. Change from Baseline in annualized number of fractures by body location and overall

    Assessed by radiological imaging and clinical examination.

    Time frame: From baseline up to 30 days after the last palovarotene dose.

  20. Incidence of pregnancy

    A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy and the health status of the baby will be verified

    Time frame: From Baseline and every month up to 30 days after the last palovarotene dose.

  21. Description of pregnancy characteristics and outcomes

    A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

    Time frame: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

  22. Description of pregnancy related Adverse Events (AEs)

    A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

    Time frame: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

  23. Description of birth and developmental outcomes through the first year after birth

    A pregnant participant with FOP exposed to palovarotene will be followed throughout the pregnancy.

    Time frame: From the signing of the ICF and the participant will be followed throughout the pregnancy (From Baseline and every month up to 30 days after the last palovarotene dose) and the health status of the baby will be verified up until one year of age.

  24. Description of birth and developmental outcomes through the first year after birth

    Linear height and knee height velocity will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

    Time frame: From Baseline and every six months up to eleven years.

  25. Change from Baseline in height z-score

    Linear height z-score will be derived for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

    Time frame: From Baseline and every six months up to eleven years.

  26. Mean difference between chronological age and bone age

    Bone age (assessment as per the SmPC/PI) and chronological age will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

    Time frame: From Baseline and every six months up to eleven years.

  27. Frequency of premature physeal closure (PPC) overall

    Epiphyseal status ("open" or "closed") (assessment as per the SmPC/PI) will be collected for growing children with FOP exposed and unexposed to palovarotene until skeletal maturity or final adult height is reached.

    Time frame: From baseline up to 30 days after the last palovarotene dose

  28. Mean dose/year of palovarotene for participants with FOP exposed and unexposed to palovarotene for chronic treatment

    Time frame: From Baseline and every six months up to eleven years.

  29. Mean dose/cycle of palovarotene for participants with FOP exposed and unexposed to palovarotene for flare-up treatment

    Time frame: From Baseline and every six months up to eleven years.

07

Study locations

4 of 5 sites recruiting
  • The Regents of the University of California
    San Francisco, California 94103, United States
    Recruiting
  • The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Edmonton Clinic Health Academy (ECHA)- University of Alberta
    Edmonton, Canada
    Recruiting
  • Bone Research and Education Centre
    Oakville, Canada
    Active, not recruiting

    Not enrolling at this site.

  • University Health Network (UHN) - Toronto General
    Toronto, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2035, 132 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 18, 2023
StartActual
Dec 5, 2024
Primary completionEst.
Dec 5, 2035
CompletionEst.
Dec 5, 2035
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 1, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06089616
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Dec 5, 2024
Primary completion
Dec 5, 2035 (estimated)
Completion
Dec 5, 2035 (estimated)
Last update
Oct 23, 2026

Study contacts

Ipsen Clinical Study Enquiries
Contact
clinical.trials@ipsen.com
see email
Ipsen Medical, Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion